Clinical Trials Logo

Clinical Trial Summary

This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.


Clinical Trial Description

Data of Patients who received PDOX after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05766605
Study type Interventional
Source Zhujiang Hospital
Contact Mingxin Pan, Prof.
Phone +8618928918216
Email pmxwxy@sohu.com
Status Recruiting
Phase Phase 3
Start date January 1, 2023
Completion date January 30, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT06157060 - Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Not yet recruiting NCT04850040 - A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin Phase 2
Not yet recruiting NCT06449846 - Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Completed NCT06294808 - Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Recruiting NCT06003673 - A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC Phase 4
Completed NCT04177316 - Hypermethylation of VTRNA2-1 Promoter in HCC Outcome